Table 1.
Baseline Characteristics by Treatment Group
| Placebo (N = 18) | Metformin (N = 19) | |
|---|---|---|
| Age, y | 15.5 (2.2) | 15.8 (2.1) |
| Sex: female, n (%) | 8 (44) | 12 (63) |
| Race/ethnicity, n (%) | ||
| White | 13 (72) | 16 (84) |
| Non-Hispanic black | 1 (6.3) | 1 (5.3) |
| Hispanic white | 3 (18.8) | 2 (10.5) |
| Other | 1 (6) | |
| Tanner stage (4 or 5), n (%) | 15 (81) | 17 (91) |
| Duration of diabetes, y | 7.2 ± 3.1 | 6.9 ± 3.7 |
| Weight, kg | 85.2 ± 17.7 | 86.7 ± 17.0 |
| FFM, kg | 49.8 ± 9.0 | 49.8 ± 9.9 |
| Waist circumference, cm | 98.3 ± 13.3 | 97.0 ± 13.0 |
| BMI, percentile | 96.7 ± 2.3 | 96.3 ± 2.5 |
| BMI z score | 1.9 ± 0.3 | 1.9 ± 0.4 |
| HbA1c, % | 8.4 ± 1.0 | 9.2 ± 1.1a |
| HbA1c, mmol/mol | 68.3 ± 8.6 | 77 ± 9.7a |
| TDI/kg | 1.03 (0.87, 1.16) | 1.03 (0.91, 1.31) |
| Steady-state GIR, corrected for serum glucose, mg/kg/min | 5.0 ± 2.5 | 4.8 ± 2.8 |
Data are shown as mean ± SD or median (25th percentile, 75th percentile).
a
P < 0.05 to 0.01.